Bausch Health Reports Strong Q3 2024 Earnings with Revenue and EBITDA Growth
Bausch Health (BHC) reported strong Q3 2024 earnings, with revenue growth of 7% and adjusted EBITDA rising 9% year over year. The company also raised its full-year guidance, indicating confidence in its performance. Key segments like Salix and Solta showed significant growth, while the international segment also contributed positively.
Tickers: $BHC
Topics: cash flow earnings EBITDA guidance revenue growth segment performance